CDK4/6抑制剂治疗三阴性乳腺癌的研究进展

细胞周期的调控机制在肿瘤的发生、发展中发挥着重要作用。多项研究表明，在雌激素受体阳性、人类表皮生长因子受体阴性的乳腺癌患者中，细胞周期蛋白依赖性激酶4/6（cyclin-dependent kinase 4/6，CDK4/6）抑制剂具有较好的疗效，然而其在三阴性乳腺癌患者中的疗效仍需进一步探讨。Cyclin D-CDK4/6-INK4-Rb-E2F信号通路因具有调控细胞周期检查点的作用，被认为是乳腺癌潜在的治疗靶点。寻找三阴性乳腺癌与CDK4/6抑制剂关联的生物标志物，探究合理的药物配伍，筛选能从中获益的靶向人群，对临床工作具有重要意义。对CDK4/6抑制剂在三阴性乳腺癌的研究进展进行综述，探讨其应用前景及优化手段。

Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors

The regulatory mechanism of cell cycle plays an important role in the occurrence and development of tumors. In recent years, a number of studies have shown that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have good efficacy in patients with estrogen receptor-positive, human epidermal growth factor receptor-negative breast cancer, but their efficacy in patients with triple-negative breast cancer is still controversial. Cyclin D-CDK4/6 -INK4-Rb-E2F signaling pathway is considered as a potential therapeutic target for breast cancer due to its role in regulating cell cycle check points. It is of great significance to explore the molecular markers related to CDK4/6 inhibitors for triple-negative breast cancer, guide rational drug combination, and screen the population of triple-negative breast cancer patient who can benefit from this drug. In this article, we reviewed the research progress of CDK4/6 inhibitors in triple-negative breast cancer, and discussed their application prospects and optimization methods.